In the years since hybridoma technology was invented, over 100 mAbs have entered the clinic and this class of drugs represents one of the fastest-growing areas of research and development. However, the production of hybridomas is ridden with potential bottlenecks and involves several steps, including the inoculation of mice with specific antigens, isolation of antibody-secreting …

Laboratory professionals in all areas of science have experienced significant changes in recent years, and 2022 was no exception. As steady progress continues in returning to normalcy as we’ve learned how to manage COVID-19, the emergence of mpox last year brought a new set of challenges for healthcare professionals, laboratories and diagnostics developers to navigate. …

Bispecific antibodies (BsAb) are promising biotherapeutics for an increasing range of diseases. There are currently seven BsAb approved by the U.S. Food and Drug Administration (FDA) and/or the European Medicines Agency (EMA) for a range of indications: Relapsed or refractory precursor B-cell acute lymphoblastic leukemia Bleeding due to hemophilia A Non-small cell lung cancer Unresectable …

RAS proteins are present in all mammalian cells where they act as signal transducers for pathways regulating cell growth, proliferation, differentiation, and survival. More than 150 human RAS proteins have been identified to-date. Mutations in this protein family have been found to drive more than 30% of all human cancers. The KRAS isoform is of …

In the 2010s, regulatory agencies made data integrity of computerized systems a central concern. While data integrity is not a new topic – electronic-specific enforcement began in the U.S. in 1997 – pharmaceutical companies now face heightened scrutiny over their practices. PerkinElmer realizes the challenges that accompany documenting electronic processes and has created a solution …

Chemistry, manufacturing, and control (CMC) information about an investigational new drug is a vital part of every clinical trial application. CMC is used to ensure the safety, identity, quality, purity, strength, and potency of the investigational drug. CMC information must also be updated as a drug proceeds through clinical trials. Following successful clinical trials, the …

We may have taken poetic liberty on Julius Caesar’s quote, but the point is clear: More than ever, we need the best minds working the best tools conquering the biggest challenges. To that point, pre-clinical drug development workflow includes toxicity evaluation at iteratively higher biological levels: cellular, tissue, organ, and whole organism. The ability to …

The pre-clinical drug development workflow includes toxicity evaluation at iteratively higher biological levels: cellular, tissue, organ, and whole organism. The ability to model and image at each of these levels is a powerful tool for molecule evaluation and development. Ex vivo 3D cellular modeling and imaging is a valuable early step in a candidate molecule’s …

Antibody therapies have become an important tool in treating diverse conditions such as autoimmune diseases, cardiovascular diseases, allergic conditions, infectious diseases, and cancers. Proven methods for developing such antibody therapies include using mice with genetically humanized immune systems and human B cells to produce fully human antibodies. These approaches have recently been used to develop …

As the effects of the novel virus are felt worldwide, researchers across the globe are mobilizing to find anti-viral therapies to fight against this new infection. Tackling this challenge by traditional de novo drug discovery approaches is a critical piece of the puzzle but also demands time and sizable investments. As an alternative approach, screening …